Comparison of improved prognosis between hepatitis B‐ and hepatitis C‐related hepatocellular carcinoma

Minami, Tatsuya; Tateishi, Ryosuke; Shiina, Shuichiro; Nakagomi, Ryo; Kondo, Mayuko; Fujiwara, Naoto; Mikami, Shintaro; Sato, Masaya; Uchino, Katsuyoshi; Enooku, Kenichiro; Nakagawa, Hayato; Asaoka, Yoshinari; Yoshida, Haruhiko; Koike, Kazuhiko

doi:10.1111/hepr.12468

Cited by 16 publications

(14 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, the HCC risk gene signature quantitatively depicted the relative risk status of the liver according to etiology (Figure 1A). HBV-infected liver showed relatively lower risk status (p<0.001, Kolmogorov-Smirnov test) consistent with the clinical observation that HBV-related HCC is associated with less frequent post-surgical/ablative HCC development compared to HCV in both Western and Eastern patient cohorts (Franssen et al, 2014; Minami et al, 2015). In contrast, NAFLD/NASH-affected livers accumulated on the higher risk side (p<0.001) despite the lowest frequency of established cirrhosis (23% in NAFLD, 21% in NASH).…”

Section: Resultssupporting

confidence: 82%

Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition

et al. 2016

View full text Add to dashboard Cite

SUMMARY Cirrhosis is a milieu that develops hepatocellular carcinoma (HCC), the second most lethal cancer worldwide. HCC prediction and prevention in cirrhosis are key unmet medical needs. Here we have established an HCC risk gene signature applicable to all major HCC etiologies: hepatitis B/C, alcohol, and non-alcoholic steatohepatitis. A transcriptome meta-analysis of >500 human cirrhotics revealed global regulatory gene modules driving HCC risk and lysophosphatidic acid pathway as a central chemoprevention target. Pharmacological inhibition of the pathway in vivo reduced tumors and reversed the gene signature, which was verified in organotypic ex vivo culture of patient-derived fibrotic liver tissues. These results demonstrate the utility of clinical organ transcriptome to enable a strategy, reverse-engineering precision cancer prevention.

show abstract

Section: Resultssupporting

confidence: 82%

Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Some studies have also suggested that IFN therapy can reduce the risk of HCC [4][5][6]. However, until recently, IFN-containing regimens have shown unsatisfactory SVR rates in patients with advanced fibrosis or cirrhosis due to lower dose intensity and adherence as a result of more severe adverse effects in these patients [7][8][9]. Currently, IFN-free, all-oral regimens with direct-acting antivirals (DAAs) have shown nearly 100% SVR rates in patients not suitable for IFN-containing regimens [10][11][12].…”

Section: Introductionmentioning

confidence: 99%

Improved liver function in patients with cirrhosis due to chronic hepatitis C virus who achieve sustained virologic response is not accompanied by increased liver volume

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background Serum albumin level improves in patients with chronic hepatitis C virus (HCV) infection who achieve sustained virologic response (SVR) with antiviral therapy. However, it remains controversial whether liver volume increases along with SVR. Methods Patients with chronic HCV infection with a history of hepatocellular carcinoma (HCC) who achieved SVR with anti-HCV treatment from March 2003 to November 2017 were enrolled. Patients were followed up with periodic computed tomography (CT) scans to detect HCC recurrence. Patients who underwent treatment for HCC recurrence within 1 year after initiation of anti-HCV treatment were excluded. Laboratory data, including alanine aminotransferase (ALT) level, serum albumin level, and platelet count, were collected at baseline and timepoints after treatment initiation. Liver volume was evaluated at baseline and 24 and 48 weeks after treatment initiation using a CT volume analyzer. A linear mixed-effects model was applied to analyze the chronologic change in liver volume. The correlations between changes in ALT level, albumin level, and liver volume were also evaluated. Results Of 108 enrolled patients, 78 had cirrhosis. Serum albumin level continued to increase through 48 weeks after treatment initiation. A significant increase in liver volume was observed only in patients without cirrhosis (P = 0.005). There was a significant correlation between ALT level decrease and albumin level increase (P = 0.018).

show abstract

“…Regarding patient characteristics, only HCVAb positivity was a negative predictor of liver volume recovery, with marginal significance. This could be because HCV‐positive patients have incurred more liver damage due to chronic hepatitis . Regarding tumor‐related factors, tumor size was not associated with liver volume recovery.…”

Section: Discussionmentioning

confidence: 96%

Ischemic complications after percutaneous radiofrequency ablation of liver tumors: Liver volume loss and recovery

Wake

Tateishi

Nakagomi

et al. 2019

Hepatology Research

Self Cite

View full text Add to dashboard Cite

Aim: The liver regrows after acute liver injury and liver resection. However, it is not clear whether the liver regenerates in advanced cirrhosis. This study aimed to evaluate the clinical course of, and liver volume change after, ischemic liver complications caused by radiofrequency ablation (RFA) of hepatocellular carcinoma (HCC). Methods:We enrolled 35 patients with ischemic complications after RFA. Ischemic complications were defined as rapid elevation of aspartate aminotransferase (AST) to over 500 U/L, with typical radiological findings. Patient characteristics and the ischemic liver volume were investigated. Long-term liver volume changes at 3-8 months after ischemic complications were also assessed in 32 patients. We also assessed the overall survival rate after ischemic complications.Results: The median value of peak AST was 798 U/L (range, 531-4096 U/L). The median ischemic liver volume relative to the functional liver volume before RFA was 13% (range, 3.1-46.5%). There was a strong correlation between the peak AST value and the ischemic liver volume (r = 0.84, P < 0.001). The liver volume recovered to some extent in 18 of 32 (56%) patients after ischemic complications. The survival rate after ischemic complications was 45.7% at 5 years and correlated with the functional liver volume after ischemic complications (P = 0.02).Conclusions: Ischemic complications after RFA can lead to massive liver parenchymal loss. Although the liver volume recovered to some extent in the majority of our patients, ischemic liver complications after RFA should be avoided to improve the overall survival rate.

show abstract

Comparison of improved prognosis between hepatitis B‐ and hepatitis C‐related hepatocellular carcinoma

Cited by 16 publications

References 38 publications

Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition

Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition

Improved liver function in patients with cirrhosis due to chronic hepatitis C virus who achieve sustained virologic response is not accompanied by increased liver volume

Ischemic complications after percutaneous radiofrequency ablation of liver tumors: Liver volume loss and recovery

Contact Info

Product

Resources

About